Scientia, based in Cambridge, Mass., and Palo Alto, Calif., reports that the market for neurostimulation devices has been growing at an average rate of 16 percent since 2007.
Through 2012, the company projects growth rates of 14 to 23 percent for deep brain stimulation, to treat movement disorders such as Parkinson’s disease; for spinal cord stimulation, to treat chronic pain; and for sacral nerve stimulation, used mainly as a last resort for serious bladder or fecal incontinence.
Read Scientia’s press release on the future of the neurostimulation market.
